Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 10/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 9/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 9/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA4 | P22748 | 2/20 | 0.55 |
| ▸ | CA6 | P23280 | 2/20 | 0.55 |
| ▸ | GSK3B | P49841 | 9/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12249832 | 0.92 | CDK1 (0.84) | CDK1CCNB2CCNB1CCNB3MAPT | |
| SCHEMBL15759621 | 0.84 | CDK1 (0.72) | CDK1CCNB2CCNB1CCNB3MAPT | |
| SCHEMBL1394921 | 0.84 | CCNB2 (0.71) | CDK1CCNB2CCNB1CCNB3MAPT | |
| SCHEMBL1987531 | 0.80 | CCNB2 (0.67) | CDK1CCNB2CCNB1CCNB3MAPT | |
| SCHEMBL15451583 | 0.80 | CDK1 (0.67) | CDK1CCNB2CCNB1CCNB3MAPT | |
| SCHEMBL4552964 | 0.77 | CDK1 (0.62) | CDK1CCNB2CCNB1CCNB3MAPT | |
| SCHEMBL16433455 | 0.77 | LMNA (0.68) | CDK1CCNB2CCNB1CCNB3MAPT | |
| SCHEMBL31721163 | 0.77 | LMNA (1.00) | CDK1CCNB2CCNB1CCNB3MAPT | |
| SCHEMBL2360729 | 0.77 | LMNA (1.00) | CDK1CCNB2CCNB1CCNB3MAPT | |
| SCHEMBL21474134 | 0.75 | CA1 (0.67) | CDK1CCNB2CCNB1CCNB3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2825637-A1 | HIGH-THROUGHPUT IMAGE-BASED CHEMICAL SCREENING IN ZEBRAFISH BLASTOMERE CELL CULTURE | Children's Medical Center Corporation (US) | 2015-01-21 | — | — | EP | claimed |
| WO-2013138623-A1 | HIGH-THROUGHPUT IMAGE-BASED CHEMICAL SCREENING IN ZEBRAFISH BLASTOMERE CELL CULTURE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2013-09-19 | — | — | WO | claimed |
| US-20180112182-A1 | HIGH-THROUGHPUT IMAGE-BASED CHEMICAL SCREENING IN ZEBRAFISH BLASTOMERE CELL CULTURE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-04-26 | — | — | US | disclosed |
| US-9771560-B2 | High-throughput image-based chemical screening in zebrafish blastomere cell culture | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| US-20150147807-A1 | HIGH-THROUGHPUT IMAGE-BASED CHEMICAL SCREENING IN ZEBRAFISH BLASTOMERE CELL CULTURE | HOWARD HUGHES MEDICAL INSTITUTE | 2015-05-28 | — | — | US | disclosed |
| EP-2825637-A1 | HIGH-THROUGHPUT IMAGE-BASED CHEMICAL SCREENING IN ZEBRAFISH BLASTOMERE CELL CULTURE | Children's Medical Center Corporation (US) | 2015-01-21 | — | — | EP | disclosed |
| WO-2014172616-A2 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-23 | — | — | WO | disclosed |
| WO-2013138623-A1 | HIGH-THROUGHPUT IMAGE-BASED CHEMICAL SCREENING IN ZEBRAFISH BLASTOMERE CELL CULTURE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2010048273-A2 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-7232814-B2 | Use of paullone derivatives for making medicines | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2007-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SOD1, NEFM | CDK1 1998/4885CCNB2 2667/4885CCNB1 2331/4885 |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, CLN6, SNCA | CDK1 2055/4885CCNB2 2803/4885CCNB1 2776/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | CDK1 3289/4885CCNB2 4196/4885CCNB1 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.